Mice treated with the S1PR2 inhibitor JTE013 or S1PR2KO showed decreased liver fibrosis, as demonstrated by reduced Sirius Red staining, hydroxyproline content, and αSMA expression (Fig 3B and 3C). This evidence concerns the gene S1PR2 and Hepatic fibrosis.